These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17227788)

  • 1. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review.
    Ferreira-González I; Dos-Subirá L; Guyatt GH
    Eur Heart J; 2007 Feb; 28(4):469-77. PubMed ID: 17227788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
    JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kheiri B; Barbarawi M; Zayed Y; Hicks M; Osman M; Rashdan L; Kyi HH; Bachuwa G; Hassan M; Stecker EC; Nazer B; Bhatt DL
    Circ Arrhythm Electrophysiol; 2019 Nov; 12(11):e007600. PubMed ID: 31698933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.
    Droogan C; Patel C; Yan GX; Kowey PR
    Heart Fail Clin; 2011 Apr; 7(2):195-205, viii. PubMed ID: 21439498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
    Lee CH; Nam GB; Park HG; Kim HY; Park KM; Kim J; Choi KJ; Kim YH
    Circ J; 2008 Jan; 72(1):102-5. PubMed ID: 18159108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.
    Pacifico A; Hohnloser SH; Williams JH; Tao B; Saksena S; Henry PD; Prystowsky EN
    N Engl J Med; 1999 Jun; 340(24):1855-62. PubMed ID: 10369848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable defibrillators and/or amiodarone: alternatives or complementary therapies.
    Dorian P; Newman D; Greene M
    Int J Clin Pract; 1998 Sep; 52(6):425-8. PubMed ID: 9894382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of drug therapy on frequency of adequate discharges of implanted cardioverter defibrillator].
    Tiroke A; Ganeeva ON
    Kardiologiia; 2003; 43(6):54-8. PubMed ID: 12891312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable defibrillators trial.
    Exner DV; Sheldon RS; Pinski SL; Kron J; Hallstrom A
    Am Heart J; 2001 Jan; 141(1):99-104. PubMed ID: 11136493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients.
    AlTurki A; Proietti R; Russo V; Dhanjal T; Banerjee P; Essebag V
    Pharmacol Res; 2019 May; 143():133-142. PubMed ID: 30914300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.
    Dorian P; Al-Khalidi HR; Hohnloser SH; Brum JM; Dunnmon PM; Pratt CM; Holroyde MJ; Kowey P;
    J Am Coll Cardiol; 2008 Sep; 52(13):1076-83. PubMed ID: 18848141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death.
    Heidenreich PA; Keeffe B; McDonald KM; Hlatky MA
    Am Heart J; 2002 Sep; 144(3):422-30. PubMed ID: 12228778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approach to antiarrhythmic therapy in patients with ICDs and frequent activations.
    Pinter A; Dorian P
    Curr Cardiol Rep; 2005 Sep; 7(5):376-81. PubMed ID: 16105494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
    Dorian P; Borggrefe M; Al-Khalidi HR; Hohnloser SH; Brum JM; Tatla DS; Brachmann J; Myerburg RJ; Cannom DS; van der Laan M; Holroyde MJ; Singer I; Pratt CM;
    Circulation; 2004 Dec; 110(24):3646-54. PubMed ID: 15533855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.